The new method is expected to significantly improve the cure rate of melanoma immunotherapy

A highly personalized approach could significantly enhance the ability of immune cells to identify and kill melanoma cancer cells, significantly increasing the cure rate for melanoma patients with immunotherapy, according to a new study published by the Weizmann Institute of Science in Israel.
Current immunotherapy consists of two main types, one is to inject antibodies to activate the patient's immune T cells to identify and kill cancer cells, and the other is to culture these T-cells in vitro and then re-inject them into the patient for treatment. But immunotherapy is conditional on T-cells recognizing labels that label cancer cells as foreign heterogeneous, otherwise they will not work.
the Weizmann Institute of Science in Israel, several research teams around the world are currently working to find cancer markers, new antigens located on the cell membranes of cancer cells. However, it is extremely difficult to find these new antigens in melanoma because they are present in a protein complex called human white blood cell antigens (HLA), which has thousands of versions.
researchers have developed a new way to isolate new antigens from melanoma-related protein complexes and then study their interactions with T-cells. The study found that almost all new antigens are unique and unique to cancer patients and specific cancer tissues.
uniqueness makes these newborn antigens the ideal anti-cancer target, which promises to create highly personalized melanoma treatments for patients, said Adena Samuels, director of research at the University of New Development.
researchers conducted experiments in laboratory petri dishes and mice and found that newborn antigen-specific T cells killed more than 90 percent of melanoma target cells.
, immunotherapy has a cure rate of about 50% for some melanoma patients. The researchers believe their new approach promises to further improve the cure rate. The findings appear in a new issue of the
Journal. (Source: Xinhua News Agency, Chen Wenxian, Du Zhen